Lorelei J. Hanson

2.2k total citations
20 papers, 1.8k citations indexed

About

Lorelei J. Hanson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lorelei J. Hanson has authored 20 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lorelei J. Hanson's work include Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Lorelei J. Hanson is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Lorelei J. Hanson collaborates with scholars based in United States, Israel and Ukraine. Lorelei J. Hanson's co-authors include Alex A. Adjei, Charles Erlichman, Jeff A. Sloan, Joel M. Reid, Laura M. Bruzek, Randolph S. Marks, Pamela J. Atherton, Scott H. Kaufmann, Henry C. Pitot and Steven R. Alberts and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Mayo Clinic Proceedings.

In The Last Decade

Lorelei J. Hanson

20 papers receiving 1.8k citations

Peers

Countries citing papers authored by Lorelei J. Hanson

Since Specialization

Citations

This map shows the geographic impact of Lorelei J. Hanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorelei J. Hanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorelei J. Hanson more than expected).

Fields of papers citing papers by Lorelei J. Hanson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorelei J. Hanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorelei J. Hanson. The network helps show where Lorelei J. Hanson may publish in the future.

Co-authorship network of co-authors of Lorelei J. Hanson

This figure shows the co-authorship network connecting the top 25 collaborators of Lorelei J. Hanson. A scholar is included among the top collaborators of Lorelei J. Hanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorelei J. Hanson. Lorelei J. Hanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors 2020 ·Investigational New Drugs ·(unknown), Julian R. Molina, Grace K. Dy, Gary A. Croghan, Yingwei Qi, James F. Glockner, Lorelei J. Hanson, (unknown), Angelina D. Tan, Alex A. Adjei	11
2	Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers 2008 ·Journal of Clinical Oncology ·Alex A. Adjei, Roger B. Cohen, Wilbur A. Franklin, Clive Morris, David M. Wilson, Julian R. Molina, Lorelei J. Hanson, Lia Gore, Laura Q.M. Chow, Stephen Leong, Lara Maloney, Gilad S. Gordon, Heidi Simmons, Allison Marlow, Kevin Litwiler, (unknown), G Pöch, Katie Kane, Jerry Haney, Sabine Eckhardt	476
3	Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer 2007 ·Clinical Cancer Research ·Alex A. Adjei, Julian R. Molina, Sumithra J. Mandrekar, Randolph S. Marks, (unknown), Gary A. Croghan, Lorelei J. Hanson, James R. Jett, Chenghua Xia, Chetan Lathia, Ronit Simantov	81
4	A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies 2006 ·Cancer Chemotherapy and Pharmacology ·X. Cynthia, Sumithra J. Mandrekar, Steven R. Alberts, Gary A. Croghan, Aminah Jatoi, Joel M. Reid, Lorelei J. Hanson, Laura M. Bruzek, Angelina D. Tan, Henry C. Pitot, Charles Erlichman, James R. Wright, Alex A. Adjei	35
5	A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors 2005 ·Cancer Chemotherapy and Pharmacology ·Grace K. Dy, Ajit Suri, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Pamela J. Atherton, Lorelei J. Hanson, Patrick A. Burch, Joseph Rubin, Charles Erlichman, Alex A. Adjei	21
6	A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer 2005 ·Cancer Chemotherapy and Pharmacology ·Grace K. Dy, Sumithra J. Mandrekar, Prema P. Peethambaram, Scott H. Okuno, (unknown), Lorelei J. Hanson, Alfred Furth, Alex A. Adjei	7
7	A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer 2005 ·Clinical Cancer Research ·Grace K. Dy, James P. Thomas, George Wilding, Laura M. Bruzek, Sumithra J. Mandrekar, Charles Erlichman, Dona Alberti, Kim Binger, Henry C. Pitot, Steven R. Alberts, Lorelei J. Hanson, Rebecca Marnocha, Kendra D. Tutsch, Scott H. Kaufmann, Alex A. Adjei	58
8	Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies 2005 ·Journal of Clinical Oncology ·Patricia LoRusso, Alex A. Adjei, Mary Varterasian, Shirish M. Gadgeel, Joel M. Reid, David Mitchell, Lorelei J. Hanson, Pamela DeLuca, Laura M. Bruzek, Jill Piens, (unknown), Keri Van Becelaere, Román Herrera, Judith S. Sebolt–Leopold, Mark B. Meyer	316
9	A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer 2005 ·Clinical Cancer Research ·Grace K. Dy, Laura M. Bruzek, Gary A. Croghan, Sumithra J. Mandrekar, Charles Erlichman, Prema P. Peethambaram, Henry C. Pitot, Lorelei J. Hanson, Joel M. Reid, Alfred Furth, Shinta Cheng, Robert E. Martell, Scott H. Kaufmann, Alex A. Adjei	23
10	Complementary and Alternative Medicine Use by Patients Enrolled Onto Phase I Clinical Trials 2004 ·Journal of Clinical Oncology ·Grace K. Dy, (unknown), Lorelei J. Hanson, Alfred Furth, Sumithra J. Mandrekar, Jeff A. Sloan, Alex A. Adjei	98
11	A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. 2003 ·PubMed ·Alex A. Adjei, Gary A. Croghan, Charles Erlichman, Randolph S. Marks, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Laura M. Bruzek, Pamela J. Atherton, Alain Thibault, Peter Palmer, Scott H. Kaufmann	40
12	Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer 2003 ·Journal of Clinical Oncology ·Alex A. Adjei, Ann M. Mauer, Laura M. Bruzek, Randolph S. Marks, Shauna Hillman, Susan M. Geyer, Lorelei J. Hanson, James R. Wright, Charles Erlichman, Scott H. Kaufmann, Everett E. Vokes	168
13	A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. 2003 ·PubMed ·Alex A. Adjei, Grace K. Dy, Charles Erlichman, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Pamela J. Atherton, Tanya Watanabe, Richard S. Geary, Jon Holmlund, F. Andrew Dorr	66
14	A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer 2002 ·Investigational New Drugs ·Alex A. Adjei, Joel M. Reid, Charles Erlichman, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, (unknown), Scott A. Boerner, Philip J. Atherton, Matthew M. Ames, Scott H. Kaufmann	6
15	Comparative Pharmacokinetic Study of Continuous Venous Infusion Fluorouracil and Oral Fluorouracil With Eniluracil in Patients With Advanced Solid Tumors 2002 ·Journal of Clinical Oncology ·Alex A. Adjei, Joel M. Reid, Robert B. Diasio, Jeff A. Sloan, Deborah A. Smith, Joseph Rubin, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Pamela J. Atherton, Matthew M. Ames, Charles Erlichman	18
16	A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. 2000 ·PubMed ·Alex A. Adjei, Charles Erlichman, J. Nathan Davis, David L. Cutler, Jeff A. Sloan, Randolph S. Marks, Lorelei J. Hanson, Phyllis A. Svingen, Pamela J. Atherton, W. Robert Bishop, Paul T. Kirschmeier, Scott H. Kaufmann	201
17	Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity 2000 ·Journal of Clinical Oncology ·Alex A. Adjei, Cheri E. Klein, Helen Kastrissios, Richard M. Goldberg, Steven R. Alberts, Henry C. Pitot, Jeff A. Sloan, Joel M. Reid, Lorelei J. Hanson, Pamela J. Atherton, Joseph Rubin, Charles Erlichman	52
18	History of the Development of Antiemetic Guidelines at Mayo Clinic Rochester 2000 ·Mayo Clinic Proceedings ·Charles L. Loprinzi, Steven R. Alberts, Bradley J. Christensen, Lorelei J. Hanson, David R. Farley, (unknown), Donna L. Betcher, (unknown), Peter A. Southorn, Todd M. Johnson, Edith A. Perez	9
19	Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid Tumors 2000 ·Journal of Clinical Oncology ·Alex A. Adjei, Charles Erlichman, Jeff A. Sloan, Joel M. Reid, Henry C. Pitot, Richard M. Goldberg, Prema P. Peethambaram, Pamela J. Atherton, Lorelei J. Hanson, Steven R. Alberts, James R. Jett	105
20	History of the Development of Antiemetic Guidelines at Mayo Clinic Rochester 2000 ·Mayo Clinic Proceedings ·Charles L. Loprinzi, Steven R. Alberts, Bradley J. Christensen, Lorelei J. Hanson, David R. Farley, (unknown), Donna L. Betcher, (unknown), Peter A. Southorn, Todd M. Johnson, Edith A. Perez	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact